Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS-1: Mirikizumab in Moderate-to-Severe Plaque Psoriasis
jRCT2080223936Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Mirikizumab arm with Placebo arm (2 arms). Started Jun 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2080223936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223936.